J
Jean-Pierre Venetz
Researcher at University of Lausanne
Publications - 62
Citations - 1205
Jean-Pierre Venetz is an academic researcher from University of Lausanne. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 19, co-authored 56 publications receiving 1107 citations. Previous affiliations of Jean-Pierre Venetz include University Hospital of Lausanne.
Papers
More filters
Journal ArticleDOI
Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients
Oriol Manuel,Manuel Pascual,Katja Hoschler,Stefano Giulieri,Deolinda Alves,Kim Ellefsen,Pierre-Alexandre Bart,Jean-Pierre Venetz,Thierry Calandra,Matthias Cavassini +9 more
TL;DR: Influenza A H1N1/09 vaccine elicited a similar antibody response in HIV-infected individuals and in control subjects, whereas SOT recipients had an overall lower response.
Journal ArticleDOI
Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.
TL;DR: It is concluded that, based on the presence of pretransplantation DSA, post-transplantation acute rejections episodes could not have been predicted and more work should be performed to better delineate the precise clinical significance of detecting low titers of DSA before transplantation.
Journal ArticleDOI
Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients.
Séverine Crettol,Jean-Pierre Venetz,Massimiliano Fontana,John-David Aubert,Nicolas Ansermot,Marc Fathi,Manuel Pascual,Chin B. Eap +7 more
TL;DR: This is the first report demonstrating that ABCB1 polymorphisms influence cyclosporine intracellular concentration, which is significantly higher than on blood concentration (P<0.002), and may therefore modulate cyclOSporine immunosuppressive activity.
Journal ArticleDOI
CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Séverine Crettol,Jean-Pierre Venetz,Massimiliano Fontana,John-David Aubert,Manuel Pascual,Chin B. Eap +5 more
TL;DR: The administration of a CYP3A genotype-dependent cyclosporine starting dose should be tested prospectively in a randomized controlled clinical trial to assess whether it leads to an improvement of the patients outcome after transplantation, with adequate immunosuppression and decreased toxicity.
Journal ArticleDOI
New treatments for acute humoral rejection of kidney allografts
TL;DR: Therapeutic strategies that include combinations of plasmapheresis (or immunoadsorption), tacrolimus, mycophenolate mofetil and/or intravenous immunoglobulins, as well as rituximab or splenectomy, have been recently used to successfully treat AHR, but the optimal protocol still remains to be defined.